Effect of fluvastatin and fenofibrate on the antioxidative barrier enzyme activity in patients with dyslipidemia;Wpływ fluwastatyny i fenofibratu na aktywność enzymów bariery antyoksydacyjnej u chorych z dyslipidemia̧

Polski Merkuriusz Lekarski

Volumn 14, Issue 82, 2003, Pages 285-288

  Kowalski, Jan ^a   Olejniczak, Jarosław ^a,b   Błaszczyk, Jan ^a   Błaszczyk Suszyńska, Joanna ^a   Kowalski, Marcin ^a   Petecka, Edyta ^a   Kȩdziora, Józef ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Oddzial Kardiologiczny Szpital   (Poland)

Author keywords

Catalase; Dyslipidemia; Glutathion peroxidase; Stable angina; Superoxide dismutase

Indexed keywords

CATALASE; FENOFIBRATE; FLUINDOSTATIN; GLUTATHIONE PEROXIDASE; SUPEROXIDE DISMUTASE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; DYSLIPIDEMIA; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; HUMAN; HYPERLIPIDEMIA; MALE; MEASUREMENT; OXIDATION; STABLE ANGINA PECTORIS;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; ANTIOXIDANTS; CATALASE; FATTY ACIDS, MONOUNSATURATED; FEMALE; GLUTATHIONE PEROXIDASE; HUMANS; HYPERLIPIDEMIAS; INDOLES; MALE; MIDDLE AGED; PROCETOFEN; SUPEROXIDE DISMUTASE;

EID: 0038374777     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Beers R. i wsp.: Spectrofotometric method for measuring the breakdown of hydrogen peroxide by catalase. J. Biol. Chem., 1952, 195, 133-140.
2. Bendich A.: Exercise and free radicals: effects of antioxidant vitamins. Med. Sport Sci., 1991, 32, 59-64.
3. Chance B. i wsp.: Hydroperoxide metabolism in mammalian organs. Physiol. Rev., 1979, 59, 527-605.
4. Chang L. i wsp.: Molecular immunocytochemistry of Cu-Zn superoxide dismutase in rat hepatocytes. J. Cell Biol., 1988, 107, 2169-2179.
5. Chen L. i wsp.: Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatheroslerotic effects of vitamin E, lovastatin and amlodipine. J. Am. Coll. Cardiol., 1997, 30, 569-575.
6. Hassan H.M.: Biosynthesis and regulation of superoxide dismutases. Free Radic. Biol. Med., 1988, 5, 377-385.
7. Heinonen T.H. i wsp.: The lipid-lowering effects of atervastatin, a new HMG-CoA reductase inhibitor: result of a double-masked study. Clin. Ther., 1986, 18, 853-863.
8. Janssen M. i wsp.: Antioxidant defences in rat, pig. guinea pig and human hearts - comparison with xanthine oxidoreductase activity. Cardiovasc. Res., 1993, 27, 2052-2057.
9. Kowalski J. i wsp.: Zaburzenia metabolizmu tlenowego w zastoinowej niewydolności serca. Możliwości ochrony farmakologicznej. Pol. Merk Lek., 1997, 3, 73-75.
10. Little C., O'Brien P.J.: An intracellular GSH-peroxidase with a lipid peroxide substrate. Bioch. Biophys. Res. Comm., 1968, 31, 145-150.
11. Meister A.: Glutathione metabolism and its selective modification. J. Biol Chem., 1988, 263, 17205-17208.
12. Misra H.P., Fridovich I.: The role of superoxide anion in the autooxidation of epinephrine and simple assay for superoxide dismutase J. Biol. Chem., 1972, 247, 3170-3175.
13. Roberts V.A. i wsp.: Mechanism and atomic structure of superoxide dismutase. Free Rad. Res. Comm., 1991, 12, 269-278
14. Rosenson R.S. i wsp.: Antiatherothrombotic properties of statins. Implications for cardiovasclar event reduction. JAMA, 1998, 279, 16431650.
15. Tkaczewski W. i wsp.: Blood platelets aggregation, malonyl dialdehyde concentration and SOD-1 activity in patients with coronary heart disease after captopril administration. In: Current advances in ACE inhibition (ed Mac Gregor G.A., Sever P.S.). London. 1989, 191-193.